Journal of Clinical Apheresis· 2026Q2
The Optimal Therapeutic Window for Nonbioartificial Liver Support in Acute‐On‐Chronic Liver Failure: A Meta‐Analysis and Meta‐Regression Based on Baseline MELD Score
- 0citations
- Q2SCImago
- 2026year
Short summary
Nonbioartificial liver support (NBALS) significantly reduces 28-day mortality in acute-on-chronic liver failure (ACLF) patients, with the greatest benefit observed in those with baseline MELD scores between 25-32.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Hepatology
HepatologyMedicine